Analysis of payments to GI physicians in the <scp>United States</scp>: Open payments data study

Gangireddy, Venu Gopala Reddy; Amin, Rajan; Yu, Kevin; Kanneganti, Praveen; Talla, Swathi; Annapureddy, Amarnath

doi:10.1002/jgh3.12401

Cited by 5 publications

(7 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, this indicates that research payments are generally much greater than general payments, exemplified by comparing the median values of research and general payments ($900 and $21, respectively). This is consistent with other publications evaluating industry payments to physicians using the Open Payments Database [ 6 , 18 ].…”

Section: Discussionsupporting

confidence: 92%

Characterizing industry payments to ophthalmologists before and after onset of the COVID-19 pandemic

Choudhry,

Burton

et al. 2023

Preprint

View full text Add to dashboard Cite

Purpose The COVID-19 pandemic had profound effects on many different aspects of our healthcare system and the relationship between industry and physicians was no exception. The present database study evaluates industry payments to ophthalmologists in order to identify whether there are significant differences in industry payments to ophthalmologists before and after onset of the pandemic. Methods The Centers for Medicare & Medicaid Services Open Payments Database was queried for all ophthalmologists who received industry payments between 2018 and 2021. Pre-Covid was defined as 2018–2019 while post-Covid was defined as 2020–2021. Payment date, value, type, company making payment, and state of recipient were recorded. The top ten companies and states in terms of payment value were included in analysis. Generalized Estimating Equations (GEE) modeling was used to assess significance. Results There were 729,263 industry payments to 20,832 ophthalmologists totaling $817,892,867.54 included for analysis in this study. We found that there was a significant increase in the mean value of research payments and a significant decrease in the mean value of general payments after the onset of the pandemic (both p < 0.001). We also report significant changes in industry payments to ophthalmologists based on the company making the payment and the state in which the ophthalmologist practices. Conclusions Our results suggest that significant differences exist in industry payment patterns to ophthalmologists following onset of the COVID-19 pandemic. Understanding underlying reasons for the observed differences may improve our understanding of the relationship between industry and clinical ophthalmology.

show abstract

Section: Discussionsupporting

confidence: 92%

Characterizing industry payments to ophthalmologists before and after onset of the COVID-19 pandemic

Choudhry,

Burton

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Similarly, Nusrat et al demonstrated that 86.9% of gastroenterologists and hepatologists received personal payments in 2016 25. The median payment per gastroenterologist in the USA was US$398–US$481 21 24. These differences between our findings and previous studies in the USA were probably due to the coverage of more general categories of payments, such as meals, travel and lodging, in the studies.…”

Section: Discussioncontrasting

confidence: 69%

“…[21][22][23] Gangireddy et al found that 12 743 US gastroenterologists and hepatologists received a median of US$398 in general payments from pharmaceutical and device companies. 24 Nusrat et al reported that 88.9% of board-certified gastroenterologists in the USA received one or more general payments from the industry in 2016. 25 They also found that gastroenterologists authoring clinical practice guidelines were likelier to make more personal payments than other general gastroenterologists.…”

Section: Introductionmentioning

confidence: 99%

“…Multiple studies conducted in the USA found that there were pervasive financial relationships between pharmaceutical companies and gastroenterologists 21–23. Gangireddy et al found that 12 743 US gastroenterologists and hepatologists received a median of US$398 in general payments from pharmaceutical and device companies 24. Nusrat et al reported that 88.9% of board-certified gastroenterologists in the USA received one or more general payments from the industry in 2016 25.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cross-sectional analysis of pharmaceutical payments to Japanese board-certified gastroenterologists between 2016 and 2019

et al. 2023

View full text Add to dashboard Cite

ObjectivesLimited evidence is available regarding the financial relationships between gastroenterologists and pharmaceutical companies in Japan. This study analysed the magnitude, prevalence and trends of personal payments made by major pharmaceutical companies to board-certified gastroenterologists in Japan in recent years.DesignCross-sectional analysisSetting and participantsUsing payment data publicly disclosed by 92 major pharmaceutical companies, this study examined the non-research payments made to all board-certified gastroenterologists by the Japanese Society of Gastroenterology.Primary and secondary outcome measuresThe primary outcomes were payment amounts, the prevalence of gastroenterologists receiving payments, yearly trends in per-gastroenterologist payment values and the number of gastroenterologists with payments. Additionally, we evaluated the differences in payments among influential gastroenterologists, including clinical practice guideline authors, society board member gastroenterologists and other general gastroenterologists.ResultsApproximately 52.8% of all board-certified gastroenterologists received a total of US$89 151 253, entailing 134 249 payment contracts as the reimbursement for lecturing, consulting and writing, from 84 pharmaceutical companies between 2016 and 2019. The average and median payments per gastroenterologist were US$7670 (SD: US$26 842) and US$1533 (IQR: US$582–US$4781), respectively. The payment value per gastroenterologist did not significantly change during the study period, while the number of gastroenterologists with payments decreased by −1.01% (95% CI: −1.61% to −0.40%, p<0.001) annually. Board member gastroenterologists (median: US$132 777) and the guideline authoring gastroenterologists (median: US$106 069) received 29.9 times and 17.3 times higher payments, respectively, than general gastroenterologists (median: US$284).ConclusionMost gastroenterologists received personal payments from pharmaceutical companies, but only very few influential gastroenterologists with authority accepted substantial amounts in Japan. There should be transparent and rigorous management strategies for financial conflicts of interest among gastroenterologists working in influential positions.

show abstract

“…In this issue of JGH Open , Dr Gangireddy and others have analyzed industry payments to gastroenterologists and hepatologists in 2017 from data available on the Open Payments website of the Centers for Medicare and Medicaid Services (CMS) in the United States 8 . Legislation requiring pharmaceutical companies to publicly disclose all payments to physicians above $10 was passed in 2010, and data have been available online since 2014.…”

mentioning

confidence: 99%

Ethics, gastroenterologists, and pharmaceutical and equipment companies

Roberts‐Thomson

2020

JGH Open

View full text Add to dashboard Cite

Analysis of payments to GI physicians in the United States: Open payments data study

Cited by 5 publications

References 27 publications

Characterizing industry payments to ophthalmologists before and after onset of the COVID-19 pandemic

Characterizing industry payments to ophthalmologists before and after onset of the COVID-19 pandemic

Cross-sectional analysis of pharmaceutical payments to Japanese board-certified gastroenterologists between 2016 and 2019

Ethics, gastroenterologists, and pharmaceutical and equipment companies

Contact Info

Product

Resources

About